AstraZeneca and AI Drug Discovery

“The potential benefits of artificial intelligence are huge, so are the dangers.” - Dave Waters

News 📰: AstraZeneca a leading adopter of AI Drug Discovery

Earlier this year it was announced that the project of collaboratively trained AI between the MELLODDY platform (namely AstraZeneca, Amgen, Astellas, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis and Servier) outperformed single-partner models on multiple axes. In particular, Owkin’…